GRAIL, Inc.
- GRAL ยท Nasdaq
- Services-Medical Laboratories
- Sunnyvale, CA
- 910 employees
- CIK 0001699031
Updated from SEC filings through
Top things to know
Executives
- Josh Ofman MD, MSHS, Chief Executive Officer of GRAIL 8-K, 2026-11-04
-
Joshua J. Ofman Chief Executive Officer 4, 2026-09-23 - Robert P. Ragusa Chief Executive Officer 4, 2026-04-09
-
Aaron Freidin Chief Financial Officer 4, 2026-09-23 - Andrew John Partridge Chief Growth Officer 4, 2026-06-05
What leadership is saying
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
GRAIL, Inc. is a U.S. public company in services-medical laboratories (SIC 8071), headquartered in Sunnyvale, CA. It trades as GRAL on Nasdaq. Revenue was $147M in the fiscal year ending December 31, 2025, +17.2% from the year before. It reported about 910 employees. Josh Ofman is MD, MSHS, Chief Executive Officer of GRAIL.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|
| Revenue | $147M 10-K, 2026-03-12 | $126M 10-K, 2026-03-12 | $93.1M 10-K, 2026-03-12 | $55.5M 10-K, 2025-03-05 |
| Operating income | -$562M 10-K, 2026-03-12 | -$2.2B 10-K, 2026-03-12 | -$1.5B 10-K, 2026-03-12 | -$5.4B 10-K, 2025-03-05 |
| SG&A | $276M 10-K, 2026-03-12 | $368M 10-K, 2026-03-12 | $363M 10-K, 2026-03-12 | $296M 10-K, 2025-03-05 |
| Net income | -$408M 10-K, 2026-03-12 | -$2.0B 10-K, 2026-03-12 | -$1.5B 10-K, 2026-03-12 | -$5.4B 10-K, 2025-03-05 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Josh Ofman | MD, MSHS, Chief Executive Officer of GRAIL | 8-K, 2026-11-04 |
| Joshua J. Ofman | Chief Executive Officer | 4, 2026-09-23 |
| Robert P. Ragusa | Chief Executive Officer | 4, 2026-04-09 |
| Aaron Freidin Chief Financial Officer at GRAIL, Inc. | Chief Financial Officer | 4, 2026-09-23 |
| Andrew John Partridge | Chief Growth Officer | 4, 2026-06-05 |
 Gregory Summe | Board member (per proxy) bio: Director and Chairperson of the Board | DEF 14A, 2026-04-28 |
| Gregory (Greg) Summe | Director and Chairperson of the Board | 10-K, 2026-03-12 |
| Sarah Krevans | Director | 10-K, 2026-03-12 |
| Steve Mizell | Director | 10-K, 2026-03-12 |
| Steven Mizell | Director | 10-K, 2026-03-12 |
| William Chase | Director | 10-K, 2026-03-12 |
What GRAIL, Inc. does
We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 45.0 million (as of November 2, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $1.9B (as of June 30, 2025) | 10-K, March 12, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting June 18, 2026 (filed April 28, 2026) | DEF 14A, April 28, 2026 |
| Auditor | Ernst & Young LLP (San Mateo, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 15, 2026 | Joshua J. Ofman Chief Executive Officer | Sale | 20,000 | $2.7M | Form 4, October 16, 2026 |
| October 5, 2026 | Andrew John Partridge Chief Growth Officer | Sale | 7,873 | $1.2M | Form 4, October 7, 2026 |
| October 5, 2026 | Aaron Freidin Chief Financial Officer | Sale | 23,619 | $3.5M | Form 4, October 7, 2026 |
| September 21, 2026 | Aaron Freidin Chief Financial Officer | Sale | 4,100 | $383K | Form 4, September 23, 2026 |
| September 21, 2026 | Joshua J. Ofman Chief Executive Officer | Sale | 61,452 | $6.0M | Form 4, September 23, 2026 |
| August 27, 2026 | Joshua J. Ofman Chief Executive Officer | Sale | 5,000 | $425K | Form 4, August 31, 2026 |
| August 27, 2026 | Aaron Freidin Chief Financial Officer | Sale | 7,900 | $672K | Form 4, August 31, 2026 |
| June 4, 2026 | Andrew John Partridge Chief Growth Officer | Sale | 1,491 | $91K | Form 4, June 5, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-22
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-01
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-19
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
- 8-K filed 2026-01-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-14
- Item 8.01 Other events
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-20
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
Frequently asked questions about GRAIL, Inc.
- What does GRAIL, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer."
- What is GRAIL, Inc.'s revenue?
- $147M for the fiscal year ending December 31, 2025, from its 10-K filed March 12, 2026.
- Is GRAIL, Inc. profitable?
- GRAIL, Inc. reported net income of -$408M for the fiscal year ending December 31, 2025.
- How many employees does GRAIL, Inc. have?
- About 910 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of GRAIL, Inc.?
- Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL, as named in a 8-K filed November 4, 2026.
- Who is the CFO of GRAIL, Inc.?
- Aaron Freidin, Chief Financial Officer, as named in a 4 filed September 23, 2026.
- Where is GRAIL, Inc. headquartered?
- Sunnyvale, CA.
- What is GRAIL, Inc.'s stock ticker?
- GRAL on Nasdaq.
- What industry is GRAIL, Inc. in?
- Services-Medical Laboratories, SIC code 8071.
- What is GRAIL, Inc.'s website?
- grail.com.
- When does GRAIL, Inc. report earnings next?
- November 11, 2026. Source: pg_earnings_events.
- Is GRAIL, Inc. a public company?
- Yes. GRAIL, Inc. files with the SEC under CIK 0001699031 and trades as GRAL.
- Who audits GRAIL, Inc.?
- Ernst & Young LLP, San Mateo, California, as named in its latest annual report (10-K).
- How many shares of GRAIL, Inc. are outstanding?
- 45.0 million shares as of November 2, 2026, from its 10-Q filed November 5, 2026.
- What is GRAIL, Inc.'s public float?
- $1.9B as of June 30, 2025, as reported on the cover of its 10-K filed March 12, 2026.
- How many business segments does GRAIL, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is GRAIL, Inc.'s annual shareholder meeting?
- June 18, 2026, per its proxy statement (DEF 14A) filed April 28, 2026.
- Have GRAIL, Inc. insiders traded stock recently?
- Since June 30, 2025, officers and directors reported 29 open-market sales worth about $46.5M and 0 purchases on Forms 4 and 5. The most recent: Joshua J. Ofman (Chief Executive Officer) sold 20,000 shares on October 15, 2026.